UBS Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $196

Benzinga · 01/07 12:46
UBS analyst Eliana Merle initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $196.